

EXEGENICS INC
Form DEFA14A
December 09, 2003

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

eXegenics Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

1) Amount previously paid:

Edgar Filing: EXEGENICS INC - Form DEFA14A

2) Form, Schedule or Registration Statement No:

3) Filing party:

4) Date Filed:

FOR IMMEDIATE RELEASE

Contact: WaLisa M. Davenport
eXegenics Inc.
(214) 358-2000

William Fiske (Information Agent)
Georgeson Shareholder Communications Inc.
Banks and Brokers: (212) 440-9800
All Others Call Toll-Free: (800) 964-0733

***eXegenics* ANNOUNCES RESULTS OF CONSENT SOLICITATION**

DALLAS, December 9, 2003 *eXegenics* Inc. (Nasdaq: EXEG) today announced that IVS Associates, Inc., the proxy inspectors engaged by *eXegenics* to provide an independent tabulation of the consents and revocations submitted in connection with the Meyers-Weiss Group consent solicitation, reported that the votes cast were sufficient to elect a new slate of directors. As a result, five nominees of the Meyers-Weiss Group were elected as directors of *eXegenics*, replacing the former board of directors. *eXegenics* stated that its officers and employees were awaiting instructions from the new board in order to effectuate the orderly transfer of corporate authority.

Safe Harbor

This release contains forward-looking statements. The words *believe*, *expect*, *intend*, *anticipate*, variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are subject to certain risks, uncertainties and assumptions that are difficult to predict. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. *eXegenics* undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.